131 related articles for article (PubMed ID: 23787480)
1. miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC.
Zhao H; Ding Y; Tie B; Sun ZF; Jiang JY; Zhao J; Lin X; Cui S
Int J Oncol; 2013 Sep; 43(3):839-49. PubMed ID: 23787480
[TBL] [Abstract][Full Text] [Related]
2. The expression of miR-30a* and miR-30e* is associated with a dualistic model for grading ovarian papillary serious carcinoma.
Wang Y; Li L; Qu Z; Li R; Bi T; Jiang J; Zhao H
Int J Oncol; 2014 Jun; 44(6):1904-14. PubMed ID: 24676806
[TBL] [Abstract][Full Text] [Related]
3. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
Yu X; Zhang X; Bi T; Ding Y; Zhao J; Wang C; Jia T; Han D; Guo G; Wang B; Jiang J; Cui S
Tumour Biol; 2013 Dec; 34(6):3501-8. PubMed ID: 23836287
[TBL] [Abstract][Full Text] [Related]
4. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
5. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
6. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma.
Zhou J; Gong G; Tan H; Dai F; Zhu X; Chen Y; Wang J; Liu Y; Chen P; Wu X; Wen J
Oncol Rep; 2015 Jun; 33(6):2915-23. PubMed ID: 25962395
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
8. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
9. MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities.
Calura E; Fruscio R; Paracchini L; Bignotti E; Ravaggi A; Martini P; Sales G; Beltrame L; Clivio L; Ceppi L; Di Marino M; Fuso Nerini I; Zanotti L; Cavalieri D; Cattoretti G; Perego P; Milani R; Katsaros D; Tognon G; Sartori E; Pecorelli S; Mangioni C; D'Incalci M; Romualdi C; Marchini S
Clin Cancer Res; 2013 Aug; 19(15):4114-23. PubMed ID: 23766361
[TBL] [Abstract][Full Text] [Related]
10. Characterization of microRNA expression in serous ovarian carcinoma.
Li Y; Yao L; Liu F; Hong J; Chen L; Zhang B; Zhang W
Int J Mol Med; 2014 Aug; 34(2):491-8. PubMed ID: 24939816
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
12. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
[TBL] [Abstract][Full Text] [Related]
13. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
14. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
[TBL] [Abstract][Full Text] [Related]
15. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
16. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancer.
Wilczyński M; Żytko E; Danielska J; Szymańska B; Dzieniecka M; Nowak M; Malinowski J; Owczarek D; Wilczyński JR
Arch Gynecol Obstet; 2018 Mar; 297(3):741-748. PubMed ID: 29335784
[TBL] [Abstract][Full Text] [Related]
18. miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations.
Teng Y; Su X; Zhang X; Zhang Y; Li C; Niu W; Liu C; Qu K
Oncotarget; 2016 Dec; 7(49):81621-81633. PubMed ID: 27835595
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer.
Cao Q; Lu K; Dai S; Hu Y; Fan W
Int J Clin Exp Pathol; 2014; 7(5):2392-401. PubMed ID: 24966949
[TBL] [Abstract][Full Text] [Related]
20. A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.
Calura E; Paracchini L; Fruscio R; DiFeo A; Ravaggi A; Peronne J; Martini P; Sales G; Beltrame L; Bignotti E; Tognon G; Milani R; Clivio L; Dell'Anna T; Cattoretti G; Katsaros D; Sartori E; Mangioni C; Ardighieri L; D'Incalci M; Marchini S; Romualdi C
Ann Oncol; 2016 Aug; 27(8):1511-9. PubMed ID: 27194815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]